| |
Our History
AMJ Laboratory Services Ltd was incorporated in 1990. The laboratory was originally situated in Guelph Ontario and moved to the Henderson Research Centre in 1994.
To better reflect our work, the name Hemostasis Reference Laboratory was registered with the Ontario Government and is used for all contracts, advertisements and publications.
Since our move to Hamilton, we have enjoyed steady growth and have continuously added new assays to our testing services.
Our Vision
We will be a leading provider of the highest quality hemostasis laboratory services through excellence in responding to the needs of our customers in a timely fashion.
We will strive to develop and provide assays for the advancement of science and the improvement of patient care.
The workplace will continue to provide employees with the training and experience for long-term growth opportunities.
 |
|
 |
NOW AVAILABLE!!
Microparticle Activity Analysis
For more information see our News and Upcoming Events page.
Genotyping for Warfarin Therapy Cytochrome
P450 2C9 gene (CYP2C9) & Vitamin K Epoxide Reductase Complex 1 gene (VKORC1) genotyping is now available. For more information see our News and Upcoming Events page.
XXII Congress of the International
Society on Thrombosis and
Haemostasis
The XXII ISTH Congress is to be held in Boston from July 11 to 16, 2009. Marilyn Johnston has had two abstracts accepted for poster presentation and publication. For more information see our News and Upcoming Events page.
Molecular Cancer Therapeutics
Article
HRL is pleased to inform of a publication by
Lucy Shin, the recipient of the HRL Scholarship for 2006, titled "Effects of the chemotherapeutic agent doxorubicon on the protein C anticoagulant pathway". For more information see our News and Upcoming Events page.
PROCALCITONIN
Testing
The B·R·A·H·M·S PCT LIA assay has been cleared by the FDA for the early diagnosis of patients at risk for progression to severe sepsis.
HRL offers Procalcitonin (PCT) testing for research purposes. The clinical utility in select patient populations has already been identified and continued studies to discover the optimal utilization of this marker as it relates to patient management is foreseen. The availability of this FDA-cleared PCT
assay will encourage further international
clinical-scientific studies. Click here to view the News and Upcoming Events page. |
|
|
